Abstract 3714
Background
The Head & Neck Primary Sarcomatoid Carcinoma (HN PSC) is a rare sub-type of squamous cell carcinoma with poor prognosis. This study sought to describe the mutational profile of HN PSC using high-throughput genotyping technology Massarray, (Agena, Hamburg).
Methods
We included 45 patients with HN PSC. We used PCR mass spectrometry detection to establish the DNA mutation profiles of 72 samples from these patients (45 primary tumors, 5 metastatic cervical nodes and 22 non tumoral tissues) studying 214 mutations affecting 26 oncogenes and tumor suppressor genes.
Results
In total, 33/45 (77.3%) patients were male and 31/45 (69%) were smokers. Median age was 60 years (range 13 – 93 years) and 28/45 (62.2%) were metastatic. The main tumor sites were oral cavities (31.1%) and larynx (28.1%). The predominant histological subtype was the pleomorphic form (66,7%). In the 72 tumors, 18 distinct somatic alterations were identified, 15 tumors (33%) harboring at least one mutation. The most frequent mutations were TP53 (11.1%), PIK3CA (8.9%), EPHA5 (4.4%), MET (4.4%), NOTCH1 (4.9%), NTRK2 (2.2%), BRAF (2.2%), JAK2 (2,2%), KRAS (2,2%) and NRF2 (2,2%). The presence of a mutation was not correlated with any clinical characteristic (age, sex, primary located site, cancer stage, tobacco and alcohol status). Only 1/45 (2.2%) tumor presented a targetable mutation with tyrosine kinase inhibitor (mutation BRAF). The mutational profile was identical between the local tumor site and the cervical node in 4/5 patients.
Conclusions
Our results demonstrated that HN PSC had a similar mutational profile of other HN carcinoma such as TP53, PIK3CA and NOTCH1 mutations. It reinforced the hypothesis of a single cell clone, which is acquired with different histological phenotypes by different, still unknown mechanisms involving epithelial to mesenchymal transition.
Clinical trial identification
Legal entity responsible for the study
Marie Wislez.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
V. Fallet: Travel, accommodations, expenses: GSK, BMS, Novartis, Boeringher Ingelheim. M. Wislez: Research funding: BMS, Boehringer Ingelheim; Consulting or advisory role: AstraZeneca, Roche, BMS, MSD, Novartis, Boehringer Ingelheim. All other authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract